Overview
GeneAgent uses explicit database lookups to ground LLM outputs, giving strong, inspectable evidence for most claims but still relies on GPT-4 and curated database coverage.
Citations2
Evidence Strength0.75
Confidence0.80
Risk Signals9
Trust Signals
Findings with numeric evidence: 5/5
Findings with evidence refs: 5/5
Results with explicit delta: 4/7
Reproducibility
Status: Partial assets available
Open source: Partial
At A Glance
Cost impact: 60%
Production readiness: 70%
Novelty: 60%
Why It Matters For Business
GeneAgent reduces false functional claims by checking LLM outputs against curated biology databases, cutting manual validation time and producing more trustworthy gene‑set summaries for research pipelines.
Who Should Care
Summary TLDR
GeneAgent is a language-agent built on GPT-4 that auto-calls curated biological databases to verify and edit its own gene-set analyses. On 1,106 gene sets from GO, NeST, and MSigDB, GeneAgent produces names and narratives closer to reference terms and reduces hallucinated functions. The system verifies individual claims against 18 domain databases via four APIs and flags or fixes unsupported claims. Manual checks and a seven‑set mouse melanoma case study show better relevance and new insights compared to vanilla GPT-4.
Problem Statement
Standard LLMs can suggest plausible but unsupported biological functions (hallucinations) for gene sets. Researchers need automated tools that combine LLM reasoning with factual checks against curated biomedical databases to produce reliable, interpretable gene‑set annotations.
Main Contribution
Design of GeneAgent: a cascaded pipeline (generate → self-verify → modify → summarize) that uses GPT-4 plus autonomous API calls to domain databases to verify claims about gene sets.
Integration with four Web APIs to access 18 curated biomedical databases (e.g., g:Profiler, Enrichr, NCBI E-utils, custom gene-centric APIs) for evidence-based verification.
Key Findings
GeneAgent increases n‑gram and LCS name overlap over GPT-4 on evaluated datasets.
GeneAgent yields higher semantic similarity to reference terms than GPT-4.
Results
| Metric | Value | Baseline | Delta | Split / Dataset | Evidence | Evidence Ref |
|---|---|---|---|---|---|---|
| ROUGE (name overlap) | MsigDB: ROUGE-1/ROUGE-L 23.9% → 31.0%; ROUGE-2 7.4% → 15.5% | GPT-4 (Hu et al.) scores | Large relative gains on MsigDB | MsigDB | Figure 2a | Figure 2a |
| Semantic similarity (MedCPT avg) | GeneAgent: 0.705, 0.761, 0.736 (three datasets) | GPT-4 average lower (stat. sig. p<0.05) | Improved average cosine similarity | GO / NeST / MSigDB (ordered as reported) | Figure 2b; Methods | Figure 2b |
What To Try In 7 Days
Run GeneAgent on recent gene lists from your lab to get evidence‑backed process names and narratives.
Integrate verification reports as synopsis for downstream enrichment or curation steps.
Mask any database that contains your ground-truth during evaluation to avoid leakage, as the paper does.
Agent Features
Memory
Planning
Tool Use
Frameworks
Is Agentic
Yes
Architectures
Collaboration
Reproducibility
Risks & Boundaries
Limitations
Backbone limited to GPT-4; other LLMs not tested.
Self-verification can incorrectly refute or endorse names when relevant databases are missing.
When Not To Use
When you require only raw GSEA p-values without narrative explanations.
When curated databases used by GeneAgent lack coverage for the species or genes of interest.
Failure Modes
Incorrectly refuting an accurate process name due to incomplete database evidence.
Incorrectly supporting a poor or hallucinated claim when matching signals are weak or noisy.